# A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

> **NCT00454246** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 111 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** methoxy polyethylene glycol-epoetin beta
- **DRUG:** epoetin alfa
- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00454246
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Strategic decision unrelated to safety or efficacy
- **Last updated:** 2011-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454246, "A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00454246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*